Skip to main content

AstraZeneca vs Pfizer: Revenue, Profit and Business Model

AstraZeneca had $58.7B of annual revenue in FY2025 and $10.2B of net income. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.

Latest financial snapshot

AstraZeneca

Latest annual revenue
$58.7B (FY2025)
Net income
$10.2B
Net margin
17.4%
Revenue growth
+11.0% a year, FY2016–FY2025

Pfizer

Latest annual revenue
$62.6B (FY2025)
Net income
$7.8B
Net margin
12.4%
Revenue growth
+1.9% a year, FY2016–FY2025

Financial summary

AstraZeneca

AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021. AstraZeneca is a massive global biopharmaceutical company, sustaining a market valuation often exceeding $200 billion.

Pfizer

Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Revenue and profit by year

AstraZeneca

AstraZeneca revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$58.7B$10.2B17.4%+8.6%Source
FY2024$54.1B$7B13.0%+18.0%Source
FY2023$45.8B$6B13.0%+3.3%Source
FY2022$44.4B$3.3B7.4%+18.5%Source
FY2021$37.4B$115M0.3%+40.6%Source
FY2020$26.6B$3.1B11.8%+9.2%Source
FY2019$24.4B$1.2B5.0%+10.4%Source
FY2018$22.1B$2B9.3%-1.7%Source
FY2017$22.5B$2.9B12.8%-2.3%Source
FY2016$23B$3.4B14.8%—Source
Full AstraZeneca financials

Pfizer

Pfizer revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$62.6B$7.8B12.4%-1.6%Source
FY2024$63.6B$8B12.6%+6.8%Source
FY2023$59.6B$2.1B3.6%-41.1%Source
FY2022$101.2B$31.4B31.0%+24.5%Source
FY2021$81.3B$22B27.0%+95.2%Source
FY2020$41.7B$9.2B22.0%+1.8%Source
FY2019$40.9B$16B39.2%+0.2%Source
FY2018$40.8B$11.2B27.3%-22.3%Source
FY2017$52.5B$21.3B40.6%-0.5%Source
FY2016$52.8B$7.2B13.7%—Source
Full Pfizer financials

Where the revenue comes from

AstraZeneca

  • Product Sales~95%

    Product Sales were $55,573 million in 2025, up 9%, or about 95% of Total Revenue. This is the direct sale of AstraZeneca-manufactured prescription medicines to wholesalers, pharmacies, hospitals and government buyers. Oncology was the largest therapy area at roughly $25.6 billion of revenue, up 17%, followed by Cardiovascular, Renal and Metabolism, with Respiratory and Immunology and Rare Disease making up most of the balance.

  • Alliance Revenue~5%

    Alliance Revenue was $3,067 million in 2025, up 39%, or about 5% of Total Revenue. It is mostly AstraZeneca's share of profits on co-commercialised medicines, led by the Enhertu and datopotamab deruxtecan antibody-drug conjugates developed with Daiichi Sankyo, plus Tezspire with Amgen and Lynparza and Koselugo with Merck in certain markets.

  • Collaboration Revenue<1%

    Collaboration Revenue was $99 million in 2025, down 89% from $923 million in 2024, so less than 1% of Total Revenue. It covers upfront fees, milestone payments and royalties on out-licensed assets, and moves sharply year to year because it depends on when individual deals are signed.

Pfizer

  • Patented medicines

    Core revenue

    Prescription drugs protected by exclusivity and clinical differentiation.

  • Vaccines

    Major revenue contributor

    Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.

  • Oncology

    Strategic growth driver

    Cancer medicines, antibody-drug conjugates, and Seagen-related assets.

  • Hospital and anti-infective products

    Meaningful contributor

    Sterile injectables, anti-infectives, and hospital therapies.

  • Collaborations and alliances

    Supplemental

    Co-promoted products and partnered scientific platforms.

Business model and strategy

AstraZeneca

How it makes money

AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company that discovers, manufactures, and markets innovative prescription medicines across four core therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases. The company's business model is centered on precision medicine and targeted biologics.

Growth strategy

AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

Competitive advantage

AstraZeneca's competitive moat is anchored by its scientific leadership in precision oncology, its pioneering partnership with Daiichi Sankyo on HER2-directed antibody-drug conjugates, and Alexion's proprietary complement inhibition biology.

AstraZeneca business model in full

Pfizer

How it makes money

Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.

Growth strategy

Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).

Competitive advantage

Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.

Pfizer business model in full

Questions about AstraZeneca vs Pfizer

Which company has higher revenue — AstraZeneca PLC or Pfizer Inc.?

AstraZeneca PLC had $58.7B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Pfizer Inc. is the larger business, with AstraZeneca PLC showing a smaller revenue base.

What is the market cap of AstraZeneca PLC vs Pfizer Inc.?

AstraZeneca PLC's market capitalisation stands at $254.6B, while Pfizer Inc.'s is $160.3B. AstraZeneca PLC carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Pfizer Inc..

How does revenue per employee compare for AstraZeneca PLC and Pfizer Inc.?

AstraZeneca PLC has $611k / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do AstraZeneca PLC and Pfizer Inc. make money?

AstraZeneca PLC and Pfizer Inc. generate revenue in fundamentally different ways. AstraZeneca PLC: AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company that discovers, manufactures, and markets innovative prescription medicines across four core therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which company is valued higher relative to revenue — AstraZeneca PLC or Pfizer Inc.?

On a price-to-sales (P/S) basis, AstraZeneca PLC trades at 4.3x P/S and Pfizer Inc. at 2.6x P/S. AstraZeneca PLC commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is AstraZeneca PLC bigger than Pfizer Inc.?

By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to AstraZeneca PLC ($58.7B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AstraZeneca vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.